Articles tagged with Ovarian Cancer
Scientists from the La Jolla Institute for Immunology found that patients with 'cold' tumors produce cancer-fighting T cells, suggesting a potential cure from within. The researchers developed an approach called 'Identify, Predict, Validate' to detect these T cells in over 130 patients.
A new study published in Oncotarget reveals a higher prevalence of germline BRCA1 and BRCA2 mutations in ovarian cancer patients from the Salento peninsula, with 28.6% having familial cases and 39.7% having sporadic cases. The study found that 29.8% of patients were carriers of BRCA1/2 mutation.
Researchers found that tumors with high levels of stroma are twice as likely to exhibit chemoresistance to conventional treatment. The study aims to utilize a readily obtainable biomarker, TSP, to tailor more effective treatments for patients diagnosed with ovarian cancer.
Researchers created Elenagen, a novel DNA immunotherapy for deadly ovarian cancer, which significantly enhances standard chemotherapy and provides clinical benefits. The study shows that Elenagen delays disease progression in patients with stage III and IV platinum-resistant ovarian cancer.
Researchers have discovered a new way to target chemotherapy-resistant ovarian cancer cells by depriving them of cholesterol, leading to significant tumor growth reduction. The nanoparticles starve the cells of cholesterol, triggering cell death through oxidation of lipids in the cell membrane.
A new method reveals genes associated with proteostasis and mRNA surveillance as important for explaining treatment resistance. The approach also identifies DNA repair deficiency as a key factor sensitizing cells to chemotherapy, PARP inhibitors, and NK killing.
Researchers have developed a new urine-based test for early detection of ovarian cancer using nanopore sensing technology. The method can simultaneously identify multiple peptides, including those derived from LRG-1, and shows promise for improving 5-year survival rates by up to 75%.
Researchers have developed an AI-driven test that accurately diagnoses ovarian cancer in women clinically classified as normal, improving detection of early-stage disease. The test uses machine learning and blood metabolite information to assign a probability of disease presence or absence, offering a more clinically informative approach.
Researchers developed an mRNA therapeutic that combats ovarian cancer by producing functional p53 protein, shrinking and killing tumors. The treatment is effective against metastases and has shown promise in preclinical studies.
Researchers found that ovarian cancer cells spread more easily in tissues that are senescent or aged due to the secretion of a unique extracellular matrix. This matrix attracts cancer cells and allows them to attach and spread faster, potentially leading to worse outcomes in older populations.
Researchers developed a training curriculum for community health workers to enhance cancer genetic screening in Black women. The 10-module program, KEEP IT, improved genetic knowledge and competencies among CHWs, who are trusted members of their communities.
A systematic analysis of cancer cells identifies 370 candidate priority drug targets across 27 cancer types. Researchers used machine learning methods to find promising targets and linked them to specific biological markers and genetic features.
Researchers unveiled a previously unknown effect of PG545 in ovarian cancer cells, inducing DNA damage and promoting autophagic degradation of RAD51. This breakthrough could aid in selecting the most appropriate treatments for ovarian cancer patients with PARPi resistance.
A Wayne State University study reports progress in a therapeutic approach that can restore immune surveillance and provide long-term protection against ovarian cancer tumors. The therapy, CARG-2020, has shown promise in animal models and may prove more effective than existing immunotherapies.
A study of 562,000 women with endometrial, ovarian, or cervical cancer reveals racial and ethnic disparities in clinical trial enrollment. Underrepresented groups face significant barriers to participation, highlighting the need for continued efforts to address these disparities.
Researchers developed novel small molecule inhibitors of CPSF3, a key regulator of transcription termination in ovarian cancer cells. These inhibitors exhibited potent antiproliferative effects and suppressed tumor growth in vivo.
Researchers Matthew Sikora and Benjamin Bitler aim to understand the genetic risk factor for ovarian cancer that varies greatly among ethnic communities. The five-year project will focus on a specific genetic variant, rs3820282, which has been linked to various gynecologic diseases.
Researchers at UNC School of Medicine have pieced together the lesser-known DNA repair pathway, polymerase theta-mediated end joining (TMEJ), which is upregulated in patients with hereditary breast cancer, ovarian cancer, and prostate cancer. The discovery could lead to new therapies for cancer by targeting this pathway.
Researchers at UCLA have developed a new method to engineer more powerful immune cells that can potentially be used for 'off-the-shelf' cell therapy to treat challenging cancers. Gamma delta T cells with high expressions of CD16 surface marker exhibited increased ability to recognize and kill cancer cells.
Researchers developed a technique to capture extracellular vesicles using sustainable wood cellulose-based nanofiber sheets, revealing new insights into cancer treatment. The technology has the potential to revolutionize early cancer diagnosis and open up personalized medicine.
Researchers at The Wistar Institute have engineered novel monoclonal antibodies that engage Natural Killer cells through Siglec-7, a conserved glyco-immune marker, to fight against cancer. These new approaches demonstrate preclinical feasibility and potential for treating treatment-resistant ovarian cancers.
A research team from the University of California - Davis Health has identified a crucial epitope on the CD95 receptor that can trigger programmed cell death in cancer cells. This finding could lead to improved cancer treatments and potentially enhance CAR T-cell therapy for solid tumors like ovarian cancer.
A new cancer immunotherapy that targets two immune-evading tumor tactics has shown promising results in an early clinical trial. The drug, tebotelimab, blocks both PD-1 and LAG-3 proteins, leading to a double-digit response rate in patients with advanced solid tumors or blood cancers.
A new blood test called OvaPrint TM detects specific nucleic acids in the blood, distinguishing between cancerous and benign pelvic masses with high accuracy. The test has the potential to improve treatment outcomes by identifying the best surgical approach for patients with a pelvic mass.
Researchers have pinpointed the molecular mechanism by which a large portion of BRCA1 mutations cause cancers in women. The study found that the E3 ligase activity of BRCA1 is crucial in several stages of DNA repair and tumor suppression, reinterpreting previous findings.
Researchers developed a low-cost, ultrasensitive blood test to detect a highly specific biomarker for multiple common cancers. The test showed promise for early cancer detection and disease monitoring, detecting levels of the biomarker in the blood of patients with many types of cancers.
A new study by Columbia University Mailman School of Public Health found that women living in more walkable neighborhoods have a lower risk of obesity-related cancers, particularly postmenopausal breast cancer. Neighborhood walkability is associated with increased physical activity and reduced car-dependency.
A Rice University-led team of researchers has been awarded $45 million to develop a new sense-and-respond implant technology that could improve immunotherapy outcomes for patients with difficult-to-treat cancers. The technology, called THOR, aims to provide real-time data from the tumor environment to guide more effective therapies.
Researchers identified four novel receptors potentially linking endometrial cancer with polycystic ovary syndrome, highlighting a major pathway involved in the increased EC risk in PCOS. The PI3K-AKT signaling pathway is consistent with a link between PCOS and EC.
A new nuclear medicine treatment has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting. The therapy targets the HER2 protein and achieved high potency while maintaining an acceptable safety profile.
Researchers found a strong positive correlation between BRD4 overexpression and chemoresistance in ovarian cancer. The study demonstrated that BRD4-L and BRD4-S isoforms play a role in promoting chemotherapy resistance in high-grade serous ovarian carcinoma.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
A Swedish study revealed that including all eleven associated genes in the screening test doubled the proportion of women with genetically confirmed hereditary breast cancer. The study included 4759 individuals and found that around 85% of women investigated for suspected hereditary breast cancer had a genetic abnormality.
Researchers successfully deployed CAR-T therapy in a mouse model of ovarian cancer, demonstrating strong anti-tumor effects even at late stages. The treatment was highly effective, shrinking or eliminating tumors after just one dose and continuing to work for months without major side effects.
Researchers have discovered a 64-protein signature that can predict which ovarian cancer patients are unlikely to respond to chemotherapy, paving the way for personalized treatment options. The study also identifies five new subtypes of high-grade serous ovarian cancer, suggesting different treatment strategies may be needed.
A secondary analysis of a randomized clinical trial found that exercise can significantly reduce symptoms of chemotherapy-induced peripheral neuropathy (CIPN) in ovarian cancer survivors. Incorporating exercise programs into standard oncology care may improve quality of life for these patients.
Researchers discovered that obesity affects ovarian cancer by altering the tumor's immune microenvironment and stiffening surrounding tissue. This change impairs treatment response to chemotherapy, leading to poorer survival rates among patients with high body mass index (BMI).
A new study reveals that cancer cells reprogram normal mesothelial cells into cancer-associated mesothelial cells through the AMH axis, promoting tumor growth and immune evasion. Disrupting this signal slows tumor growth and helps the immune system overcome some of its defenses.
A synoptic report improved the completeness of pretreatment CT reports in patients with advanced ovarian cancer. Involvement of surgically established unresectable or challenging-to-resect disease sites was mentioned in all disease-specific synoptic reports, compared to 37% of simple structured reports.
A case-control study found associations between certain jobs and increased risks of ovarian cancer. Hairdressers, beauticians, and accountants were linked to higher risks, with cumulative exposure to agents like talcum powder and ammonia also contributing.
Researchers at Nagoya University have discovered three new biomarkers for high-grade serous ovarian carcinoma using membrane proteins and polyketone-coated nanowires. The study reveals that small extracellular vesicles containing these proteins can be used to detect ovarian cancer, potentially leading to personalized medicine.
Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.
A nationwide study of nearly two million women found that those with PCOS who have undergone menopause are more than twice as likely to be diagnosed with ovarian cancer. The risk was also significantly higher for a type of ovarian tumor known as serous borderline, which can lead to cancer later on.
Researchers at Imperial College London have found that tumors with tertiary lymphoid structures (TLS) in high-grade ovarian cancer respond better to treatment. Genes like IL15 and CXCL10 play a role in TLS formation, while DCAF15 interacts with these tissues. An AI algorithm can detect TLS on CT scans, enabling early identification of ...
A new study reveals that the protein complex BCDX2 plays a critical role in DNA repair, suggesting mutations in this complex could lead to cancer. The research also highlights the importance of screening for mutations in people with a family history of breast and ovarian cancers.
Researchers found that only 6.8% of cancer patients underwent genetic testing within two years of diagnosis, with lower rates among Black, Hispanic, and Asian patients. The low rates are attributed to lack of integration of test results into cancer management and prevention.
A phase I study found significant clinical benefit of the ADC luveltamab tazevibulin in patients with recurrent ovarian cancer expressing high levels of folate receptor alpha, with an overall response rate of 37.5% and a 44% response rate at higher doses.
A UTHSC research collaboration has been awarded a national grant to develop a new treatment for ovarian cancer. The project will test a newer generation of sabizabulin, a clinical candidate targeting microtubules in cancer cells.
Researchers discuss chemotherapeutic resistance in recurring ovarian cancer, focusing on the unfolded protein response and its effect on polyploid giant cancer cells. Understanding this mechanism could lead to investigating cancer cell molecular mechanisms and potential therapeutic strategies.
The PARIS Test, a CLIA-certified drug sensitivity assay, uses patient-derived tumor organoids to screen an array of drugs and develop personalized treatment reports. Ibrutinib, a BTK inhibitor approved only for certain leukemias and lymphomas, was identified as the optimal treatment for a patient with ovarian cancer.
Researchers have identified three subtypes of ovarian high-grade serous carcinoma (HGSC) based on genomic changes, which may help tailor therapies. The study's findings could improve treatment outcomes for patients with this aggressive subtype.
Overweight and obesity in early adulthood are associated with increased risks of colorectal cancer and non-colorectal gastrointestinal cancers. The study highlights the need for further exploration into the mechanisms driving these associations.
A new study finds that one-time genomic screening of adults aged 20-60 for hereditary breast and ovarian cancer syndrome, Lynch syndrome, and familial hypercholesterolemia is cost-effective based on quality-adjusted life-year measures. The study suggests that this approach could improve disease management and reduce healthcare costs.
A recent Fred Hutchinson Cancer Center study found that fibroids were associated with an increased risk of ovarian cancer in both Black and white women, while hysterectomy modified this risk for white women but not Black women. The study highlights the need for further research into racial disparities in ovarian cancer risk.
A new study suggests combining digital cancer risk assessment with point-of-care genetic testing can help overcome clinical workflow challenges that prevent at-risk patients from accessing genetic testing. The approach more than doubled the average uptake of genetic testing, showing promise for cancer prevention and detection.
Researchers have reported promising results in rare gynecologic cancers from the DART immunotherapy trial, with durable responses and complete remissions observed in patients. The findings suggest a potential new treatment approach for these previously underserved patient populations.
Researchers found that removing ovaries during a benign hysterectomy increases the risk of hospitalization for cardiovascular disease in premenopausal women, but not necessarily for cancer. The study supports current recommendations to conserve ovaries in premenopausal patients at low risk for ovarian cancer.
A new target for drug-resistant ovarian cancer has been identified through a preclinical study led by researchers at Penn Medicine. An antibody-drug conjugate targeting B7-H4 showed significant anti-tumor activity and sustained response in treatment-resistant models.
A new study reveals the mechanism of BRCA2's DNA repair function, understanding its role in breast and ovarian cancer development. The findings also provide insights into developing targeted cancer therapies by inhibiting DNA repair mechanisms.
A phase II trial investigating the combination of ribociclib and letrozole showed a response rate of 23%, progression-free survival of 19.1 months, and duration of response of 19.1 months in patients with recurrent low-grade serous ovarian cancer.